Literature DB >> 17904949

Cubicin Outcomes Registry and Experience (CORE) methodology.

Kenneth V I Rolston1, John Segreti, Kenneth C Lamp, Lawrence V Friedrich.   

Abstract

The Cubicin Outcomes Registry and Experience (CORE), was designed to retrospectively collect the real-world postmarking experience of patients who received daptomycin. A standardized case report form was used by trained investigators from 45 institutions across the United States. Data on 1,160 patients from November 2003 until December 2004 were collected on demographics, infections, treatments and outcomes at the end of daptomycin therapy. The data from CORE 2004 provide insight into the early clinical use of daptomycin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904949     DOI: 10.1016/j.amjmed.2007.07.008

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Authors:  Pamela A Moise; Maria Amodio-Groton; Mohamad Rashid; Kenneth C Lamp; Holly L Hoffman-Roberts; George Sakoulas; Min J Yoon; Suzanne Schweitzer; Anjay Rastogi
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 2.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

3.  Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Authors:  Jason A Crompton; Donald S North; MinJung Yoon; Judith N Steenbergen; Kenneth C Lamp; Graeme N Forrest
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

4.  A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia.

Authors:  Joseph S Bubalo; Ravina Kullar; Richard T Maziarz
Journal:  Ther Adv Infect Dis       Date:  2013-12

5.  Daptomycin use in neutropenic patients with documented gram-positive infections.

Authors:  Kenneth V I Rolston; Dina Besece; Kenneth C Lamp; Min Yoon; Scott A McConnell; Pamela White
Journal:  Support Care Cancer       Date:  2013-08-24       Impact factor: 3.603

6.  Daptomycin therapy for osteomyelitis: a retrospective study.

Authors:  Jason C Gallagher; Jennifer A Huntington; Darren Culshaw; Scott A McConnell; Minjung Yoon; Elie Berbari
Journal:  BMC Infect Dis       Date:  2012-06-12       Impact factor: 3.090

7.  Clinical experience with daptomycin in Europe: the first 2.5 years.

Authors:  Armando Gonzalez-Ruiz; Andres Beiras-Fernandez; Hans Lehmkuhl; R Andrew Seaton; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2011-01-25       Impact factor: 5.790

8.  Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.

Authors:  Beth White; R Andrew Seaton
Journal:  Infect Drug Resist       Date:  2011-05-24       Impact factor: 4.003

9.  Daptomycin: local application in implant-associated infection and complicated osteomyelitis.

Authors:  Steffen B Rosslenbroich; Michael J Raschke; Carolin Kreis; Nancy Tholema-Hans; Andreas Uekoetter; Rudolf Reichelt; Thomas F Fuchs
Journal:  ScientificWorldJournal       Date:  2012-06-18

10.  A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin.

Authors:  Elizabeth D Hermsen; Luke Mendez-Vigo; Elie F Berbari; Thomas Chung; Minjung Yoon; Kenneth C Lamp
Journal:  BMC Infect Dis       Date:  2016-06-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.